The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
Open accessAbstract
Purpose: Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells. Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide. Patients and Methods: Gene expression profiles of 80 glioblastomas were interrogated for associations with resistance to therapy. Patients were treated within clinical trials testing the addition of concomitant and adjuvant temozolomide to radiotherapy. Results: An expression signature dominated by HOX genes, which comprises Prominin-1 (CD133), emerged as a predictor for poor survival in patients treated with concomitant chemoradiotherapy (n = 42; hazard ratio = 2.69; 95% CI, 1.38 to 5.26; P = .004). This association could be validated in an independent data set. Provocatively, the HOX cluster was reminiscent of a “self-renewal” signature (P = .008; Gene Set Enrichment Analysis) recently characterized in a mouse leukemia model. The HOX signature and EGFR expression were independent prognostic factors in multivariate analysis, adjusted for the O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, a known predictive factor for benefit from temozolomide, and age. Better outcome was associated with gene clusters characterizing features of tumor-host interaction including tumor vascularization and cell adhesion, and innate immune response. Conclusion: This study provides first clinical evidence for the implication of a “glioma stem cell” or “self-renewal” phenotype in treatment resistance of glioblastoma. Biologic mechanisms identified here to be relevant for resistance will guide future targeted therapies and respective marker development for individualized treatment and patient selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“M2 polarization mediates tolerance and downregulates inflammation, alleviating immune surveillance.(31,32) A wide range of CD163-positive cells can be observed in glioblastoma (Appendix Fig A5, online only).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This is in accordance with the concept suggesting that antiangiogenic agents may temporarily lead to “normalization” of aberrant tumor vasculature, resulting in more efficient delivery of drugs and oxygen to the tumor.(39,40) In a recent trial, addition of the antiangiogenic integrininhibitor cilengitide appears to co…”
ResultPhillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 4×
“As an independent predictive factor of resistance, we have identified a HOX-dominated gene cluster, evocative of a self-renewal signature recently described for leukemia.(9) Strong HOXA10 expression of glioblastoma-derived neurospheres is in line with a role of HOX genes in the glioma stem-like cell compartment.”
BackgroundResultInfluentialAquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke
Manley, G. T., Fujimura, M., Ma, T., Noshita, N., Filiz, F., Bollen, A. W., Chan, P., & Verkman, A. S. (2000) · Nature Medicine · doi:10.1038/72256 · Cited by 1,507
MLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
Piccirillo, S. G. M., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., & Vescovi, A. L. (2006) · Nature · doi:10.1038/nature05349 · Cited by 1,176
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.033 · Cited by 1,050
Self-citationStupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Self-citationCoupled two-way clustering analysis of gene microarray data
Getz, G., Levine, E., & Domany, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210134797 · Cited by 813
Self-citationHegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationGene Expression Profiling of Gliomas Strongly Predicts Survival
Freije, W. A., Castro-Vargas, F. E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L. M., Mischel, P. S., & Nelson, S. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0452 · Cited by 744
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption
Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., & Verkman, A. S. (2005) · Nature · doi:10.1038/nature03460 · Cited by 728
Epidermal growth factor receptor and Ink4a/Arf
Bachoo, R. M., Maher, E. A., Ligon, K. L., Sharpless, N. E., Chan, S. S., You, M. J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00046-6 · Cited by 652
Deregulated homeobox gene expression in cancer: cause or consequence?
Abate-Shen, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc907 · Cited by 617
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1
Hussain, S. F., Yang, D., Suki, D., Aldape, K., Grimm, E., & Heimberger, A. B. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-008 · Cited by 592
Superparamagnetic Clustering of Data
Blatt, M., Wiseman, S., & Domany, E. (1996) · Physical Review Letters · doi:10.1103/physrevlett.76.3251 · Cited by 537
Self-citationChemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8554 · Cited by 529
Self-citationChute, J. P., Muramoto, G. G., Whitesides, J., Colvin, M., Safi, R., Chao, N. J., & McDonnell, D. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603806103 · Cited by 467
Gene expression profiling of pediatric acute myelogenous leukemia
Ross, M. E., Mahfouz, R., Onciu, M., Liu, H.-C., Zhou, X., Song, G., Shurtleff, S. A., Pounds, S., Cheng, C., Ma, J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1154 · Cited by 448
Van Ginderachter, J. A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S., Beschin, A., Raes, G., & De Baetselier, P. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.06.002 · Cited by 371
Vairapandi, M., Balliet, A. G., Hoffman, B., & Liebermann, D. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10140 · Cited by 347
Kjellman, C., Olofsson, S. P., Hansson, O., Von Schantz, T., Lindvall, M., Nilsson, I., Salford, L. G., Sjögren, H.-O., & Widegren, B. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000520)89:3<251::aid-ijc7>3.0.co;2-5 · Cited by 224
New Treatment Strategies for Malignant Gliomas
Avgeropoulos, N. G., & Batchelor, T. T. (1999) · The Oncologist · doi:10.1634/theoncologist.4-3-209 · Cited by 182
Vascular Gene Expression in Nonneoplastic and Malignant Brain
Madden, S. L., Cook, B. P., Nacht, M., Weber, W. D., Callahan, M. R., Jiang, Y., Dufault, M. R., Zhang, X., Zhang, W., Walter-Yohrling, J., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63324-x · Cited by 179
New treatment strategies for malignant gliomas
Sathornsumetee, S., & Rich, J. N. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1087 · Cited by 135
Dorrance, A. M., Liu, S., Yuan, W., Becknell, B., Arnoczky, K. J., Guimond, M., Strout, M. P., Feng, L., Nakamura, T., Yu, L., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25546 · Cited by 128
Differential expression of HOX genes in neoplastic and non‐neoplastic human astrocytes
Abdel‐Fattah, R., Xiao, A., Bomgardner, D., Pease, C.-S., Lopes, M.-B., & Hussaini, I. (2006) · The Journal of Pathology · doi:10.1002/path.1939 · Cited by 83
Cited by
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
“Neuropathology: Ken Aldape(10), Darell Bigner(6), Tom Mikkelsen(8) & Scott VandenBerg(9).”
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
“…and gene expression profiling studies identifying gene signatures associated with EGFR overexpression, clinical features, and survival (Freije et al., 2004; Liang et al., 2005; Mischel et al., 2003; Murat et al., 2008; Nutt et al., 2003; Phillips et al., 2006; Shai et al., 2003; Tso et al., 2006).”
BackgroundMethodResultInfluentialWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Metadata
- Authors
- Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., Hainfellner, J. A., Heppner, F. L., Dietrich, P.-Y., Zimmer, Y., Cairncross, J. G., Janzer, R.-C., Domany, E., Delorenzi, M., Stupp, R., & Hegi, M. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-20
- Volume
- 26
- Issue
- 18
- Pages
- 3015-3024
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121625674
- Cited by
- 721
- References
- 40
- FWCI
- 20.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.